| Previous Close | 2.02 |
| Open | 1.89 |
| Day High | 2.11 |
| Day Low | 1.72 |
| 52-Week High | 15.74 |
| 52-Week Low | 1.72 |
| Volume | 172,010 |
| Average Volume | 90,461 |
| Market Cap | 4.69M |
| PE | -0.1 |
| EPS | -16.82 |
| Moving Average 50 Days | 7.64 |
| Moving Average 200 Days | 9.8 |
| Change | -0.27 |
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
GlobeNewswire Inc.
Mar 05, 2026 9:05 PM GMT
Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74 Phase 1 dose escalation trial update planned in second half of 2026 BELTSVILLE, Md., March 05
NextCure Provides Business Update
GlobeNewswire Inc.
Jan 23, 2026 12:00 PM GMT
SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-s
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced